Please provide your email address to receive an email when new articles are posted on . Both 0.03% and 0.05% atropine eyedrops significantly enlarged pupil size. Low-dose atropine drops had no ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nightly use of 0 ...

Progressive myopia is a growing issue in every country as near vision demands for children continue to increase. In 1980, ...

Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with those using placebo or 0.01% atropine, though they had higher rates of ...

A nightly use of 0.05% atropine eyedrops resulted in a lower incidence of myopia compared with placebo. Reduced incidence of myopia and myopic shift after 2 years of follow-up was seen in patients who ...

UAB School of Optometry professor is joining a national network study to research myopia prevention in children. Myopia, ...

A study that focused on children aged 5 to 12 years who lived in the United States found no difference between atropine 0.01% and placebo in treating myopia progression. Atropine 0.01% was no more ...

In a cohort of over 1.2 million Taiwanese children followed up for at least 5 years, those with myopia had a higher risk for ocular problems than those without the condition. However, among children ...

Atropine eye drops given once a day to treat amblyopia, or lazy eye, the most common cause of visual impairment in children, work as well as the standard treatment of patching one eye. This research ...

A new clinical trial has found that a common eye drop is a safe and effective way to slow the progression of nearsightedness in children. The finding may provide an easier way of treating the ...

About The Study: In this randomized clinical trial of school-age children in the U.S. with low to moderate myopia (nearsightedness), atropine, 0.01%, eye drops administered nightly when compared with ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, ...